Ex-Senator Ben Sasse Enters Groundbreaking Pancreatic Cancer Trial
Former U.S. senator Ben Sasse, diagnosed with metastatic pancreatic cancer, joined Revolution Medicines’ frontline trial of daraxonrasib. Preliminary topline data show the drug can markedly extend survival versus chemotherapy in second-line use, and Sasse reports dramatic drops in the tumor marker CA 19-9 and meaningful pain relief, with frontline use potentially even more beneficial, signaling a potential major advance in pancreatic cancer care.